Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Eli Lilly ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

STORY: Eli Lilly said Monday it will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy. That said, despite possible ...

Eli Lilly Downplays CVS Move to Drop Zepbound Coverage, Shares Plunge By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's ...

Eli Lilly (LLY) has enjoyed a successful run the ... And that's hard to do," Ricks said of the CVS deal. He also noted that the company's direct-to-consumer platform, which ties in telehealth ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Red Brook Advisors managing partner Syed Husain told Yahoo Finance that the market reaction to the CVS deal — a more than 10% decline in Eli Lilly's stock — was "a bit of an overreaction." ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

CVS's pharmacy benefit management unit ... The chart shows U.S. prescriptions for Novo Nordisk's Wegovy and Eli Lilly's Zepbound over a six month period (august 2024 to January 2025).